Nevertheless, the capex trajectory is on a decline. With proceeds from InvIT, we see strong scope for higher dividends.
Prediction of a normal monsoon, good Rabi harvest, favourably timed kharif sowing, and MNREGA provide prospective support as well. The…
On a segmental basis, the Corporate segment has reported profits after four years of consecutive losses. On the other hand,…
New products will be vital to growth; FY22e EPS cut by 7% due to Covid wave and inflation; ‘Buy’ maintained
Offtake growth in May 2021 comes on the back of: a) a 15% rise in coal-based generation (based on initial…
Notably, certain factors that led to the positive margin surprise in 4QFY21 and the full-year FY21 — resulting in all-time…
Debt level to go down; stock valuation is attractive; ‘Buy’ retained with TP of Rs 539
C/I ratio declined 200bp QoQ and 17pp YoY to 40%. The management has guided at near term C/I ratio above…
Collections have seen strong improvement; ‘Neutral’ retained with TP of Rs 370
Dr Reddy’s (DRRD) has exclusive marketing and distribution rights for the first 250m doses of Sputnik V vaccines in India.
Superior execution, market share gains to drive growth in DF. While doctors have resumed their clinics, partly on account of…
Overall fertilizer industry volumes grew 8% YoY in FY21 on the back of 19% volume growth in MOP; NPKS and…
Strong structural outlook; second Covid wave could boost FY22 EPS; valuations are inexpensive; TP up to Rs 4,575; ‘Buy’ maintained
Recovery trends steady until the second Covid-19 wave hit DMART published its Mar’21 performance, which offers a positive trend before…
SAIL, in a press release, informed that it has reduced its gross debt by Rs 161 billion (30%) in FY21…
We expect ~30% volume growth in FY22E and positive evolution of margin. We see 27% upside at our TP of…
Expects a 19% earnings CAGR over FY20–23
Product offerings and better asset utilisation to drive EPS CAGR of 38% over FY20-23; Buy retained with Rs 4,530 TP
